Dexanabinol (HU‐211): A nonpsychotropic cannabinoid with neuroprotective properties

@article{Shohami2000DexanabinolA,
  title={Dexanabinol (HU‐211): A nonpsychotropic cannabinoid with neuroprotective properties},
  author={E. Shohami and Raphael Mechoulam},
  journal={Drug Development Research},
  year={2000},
  volume={50}
}
The synthetic cannabinoid (+)‐(6aS,10aS)‐11‐hydroxy‐Δ‐8‐tetrahydrocannabinol 1′,1′‐dimethylheptyl (dexanabinol, HU‐211) is inactive as a cannabimimetic, but exhibits pharmacological properties characteristic of an N‐methyl‐D‐aspartate (NMDA)‐receptor antagonist. It blocks NMDA‐receptors stereospecifically by interacting with a site close to, but distinct from, that of uncompetitive NMDA‐receptor antagonists and from the recognition sites of glutamate, glycine, and polyamines. HU‐211 inhibits… 
The dual neuroprotective–neurotoxic profile of cannabinoid drugs
TLDR
Recent findings support the idea that this low dose of THC, which induces minor damage to the brain, may activate preconditioning and/or postconditioning mechanisms and thus will protect the brain from more severe insults and show that a pre‐ or a post Conditioning treatment with extremely low doses of THC provides effective long‐term cognitive neuroprotection.
Acute neuronal injury, excitotoxicity, and the endocannabinoid system
TLDR
Several observations indicate that the role of the endocannabinoid system as a general endogenous protection system is questionable.
The endocannabinoid system as a target for the treatment of neuronal damage
TLDR
Cannabinoids can serve this purpose given their recognized antiexcitotoxic, antioxidant and anti-inflammatory properties, and there is an urgent need for novel neuroprotective agents.
CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition
TLDR
2-AG exerts its neuroprotection after CHI, at least in part, via CB1 receptor-mediated mechanisms that involve inhibition of intracellular inflammatory signaling pathways, which was as high as in the WT vehicle-treated mice.
Immunomodulatory Properties of Kappa Opioids and Synthetic Cannabinoids in HIV-1 Neuropathogenesis
TLDR
Based upon work in other models of neuroinflammation, kappa opioid receptors (KOR) and synthetic cannabinoids have emerged as having neuroprotective properties and the ability to dampen pro-inflammatory responses of glial cells; properties that may have a positive influence in HIV-1 neuropathogenesis.
Cannabinoids and Neuroprotection in Basal Ganglia Disorders
TLDR
Considering the relevance of these preclinical data and the lack of efficient neuroprotective strategies in both disorders, it is urged the development of further studies that allow that the promising expectatives generated for these molecules progress from the present preclinical evidence till a real clinical application.
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
TLDR
It is shown that, after injury to the mouse brain, 2-AG may have a neuroprotective role in which the cannabinoid system is involved and this effect was dose-dependently attenuated by SR-141761A, an antagonist of the CB1 cannabinoid receptor.
The Endocannabinoid Anandamide : Metabolism & Neuroprotection
TLDR
Results indicate that small changes in the chemical structure of anandamide can lead to the generation of novel compounds which can specifically interact with each of the proteins of the endogenous cannabinoid system.
Endocannabinoids and Neuroprotection
TLDR
The synthesis in the brain of the endogenous cannabinoids 2-arachidonoyl glycerol (2-AG) and anandamide is enhanced in mice and rats, respectively, after TBI and reduces brain damage and represents a new class of neuroprotective agents that have multiple mechanisms of action that might improve the blood supply to the injured brain.
...
...

References

SHOWING 1-10 OF 30 REFERENCES
HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture.
TLDR
Data suggest that the neuroprotective activity of HU-211 is directly associated with the NMDA receptor channel and possibly with the quisqualate receptor of the metabotropic class.
Neuroprotective Effects of HU‐211 on Brain Damage Resulting from Soman‐Induced Seizures
TLDR
HU‐211 provides considerable neuroprotection against brain damage produced by soman‐induced seizures, and was corroborated by hemotoxylin and eosin (H&E) histopathological assessment that showed a significant reduction in piriform cortical neuronal damage in HU‐ 211‐treated animals.
Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.
Binding studies using the enantiomers of the synthetic cannabinoid 7-hydroxy-delta 6-tetrahydrocannabinol 1,1-dimethylheptyl homolog in preparations of rat brain cortical membranes reveal that the
Development of HU-211 as a neuroprotectant for ischemic brain damage.
TLDR
Observations support the development of HU-211 as a novel, multiple-action treatment approach for brain damage associated with stroke, cardiac arrest and trauma.
HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy.
TLDR
It is shown that HU-211 can reduce injury-induced metabolic and electrophysiological deficits and be used as a neuroprotective compound in the CNS.
Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils.
TLDR
HU-211, a nonpsychotropic cannabinoid and a noncompetitive NMDA antagonist, was tested in a global ischemia model in the Mongolian gerbil and demonstrated an inverted U curve in which the 4 mg/kg dose induced the best neuroprotection in the CA1 subfield of the hippocampus.
...
...